JEIL PHARMACEUTICAL CO., LTD.
🇰🇷South Korea
Observationa Study is a Prospective and Multi-institutional Observational Study.
Completed
- Conditions
- Erosive Reflux DiseaseHeartburnAcid Regurgitation
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 5536
- Registration Number
- NCT06952855
- Locations
- 🇰🇷
Goodbreath Medical Center, Seoul, Gyeonggi-do, Korea, Republic of
To Evaluate the Safety, Pharmacokinetic Characteristics and the Effect of Food After Administration of JLP-2004
Phase 1
Recruiting
- Conditions
- Healthy
- Interventions
- Drug: JLP-2004 qd
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06431399
- Locations
- 🇰🇷
Chungbuk National University Hospital, Chungju, Seowon-gu, Korea, Republic of
To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JC-001 and JLP-1901
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06171880
- Locations
- 🇰🇷
Bundang CHA university global clinical trials center Institutional Review Board, Gyeonggi-do, Bundang-gu, Korea, Republic of
To Evaluate the Safety and Pharmacokinetic Characteristics After Multiple Administration of JC-013 and JLP-2004
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06169059
- Locations
- 🇰🇷
H plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of
To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008
Phase 1
Completed
- Conditions
- Healthy Adult
- Interventions
- Drug: SGLT2 inhibitor
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06165965
- Locations
- 🇰🇷
Bundang CHA university global clinical trials center Institutional Review Board, Gyeonggi-do, Bundang-gu, Korea, Republic of
Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients
Phase 2
Not yet recruiting
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: SGLT2 inhibitor
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 156
- Registration Number
- NCT06144788
- Locations
- 🇰🇷
Severance Hospital, Seoul, Seodaemun-gu, Korea, Republic of
To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 245
- Registration Number
- NCT05296044
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Characteristics of JP-2266 in Healthy Subjects
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2021-12-29
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT05172622
- Locations
- 🇫🇷
OPTIMED clinical research, Gières, France
To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 256
- Registration Number
- NCT05101135
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder
Phase 3
Completed
- Conditions
- Overactive Bladder
- Interventions
- Drug: JLP-2002 A mgDrug: Placebo
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 210
- Registration Number
- NCT04917315
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of